Agenus Inc AJ81-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 09/30/22 CEST
2.25quote price arrow up+0.03 (+1.42%)
Volume
285
52 week range
1.23 - 5.00
Loading...
  • Open2.11
  • Day High2.25
  • Day Low2.11
  • Prev Close2.25
  • 52 Week High5.00
  • 52 Week High Date09/27/21
  • 52 Week Low1.23
  • 52 Week Low Date06/15/22

Key Stats

  • Market Cap579.86M
  • Shares Out282.86M
  • 10 Day Average Volume55
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-23.26

KEY STATS

  • Open2.11
  • Day High2.25
  • Day Low2.11
  • Prev Close2.25
  • 52 Week High5.00
  • 52 Week High Date09/27/21
  • 52 Week Low1.23
  • 52 Week Low Date06/15/22
  • Market Cap579.86M
  • Shares Out282.86M
  • 10 Day Average Volume55
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-23.26

RATIOS/PROFITABILITY

  • EPS (TTM)0.11
  • P/E (TTM)20.41
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Agenus Inc

 

Profile

MORE
Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, vaccines and adjuvants. Its antibody candidates are Balstilimab (an anti-PD-1 antibody) and Zalifrelimab (an anti-CTLA-4 antibody), which is in Phase 2 trials as both a monotherapy...
Garo Armen Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Christine Klaskin
Vice President - Finance
Address
3 Forbes Rd
Lexington, MA
02421-7305
United States